摘要
目的:探讨胃康舒宁对大鼠胃癌前病变(PLGC)的治疗机制,为临床应用提供依据。方法:将60只Wistar大鼠随机分为4组(正常组、模型组、维酶素组和胃康舒宁组),采用饮用N-甲基-N-亚硝基-N-硝基胍(MNNG)建立大鼠胃癌前病变模型,用维酶素和胃康舒宁治疗12周后,观察各组实验大鼠胃黏膜细胞凋亡指数、Bcl-2和Bax蛋白表达情况及Bcl-2/Bax比值的变化。结果:与模型组大鼠相比,用药组大鼠胃黏膜细胞凋亡指数和Bax蛋白表达明显提高,而Bcl-2蛋白表达及Bcl-2/Bax比值显著降低,胃康舒宁组明显优于维酶素组。结论:胃康舒宁通过调节病变细胞Bcl-2和Bax蛋白的异常表达,改变Bcl-2/Bax比值,使细胞凋亡趋于正常,而对大鼠胃癌前病变具有良好的治疗和逆转作用,其疗效优于维酶素。
Objective: To study the therapeutic mechanism of Weikangshu'ning on precancer lesions of gastric careinnoma (PL- GC) in rats,and offer the experimental foundation for clinical applying. Methods; 60 Wistar rats were randomly divided into control group, PLGC group, vitacoenzyme group and Weikangshu'ning group. Models of PLGC were induced by N- methly- N - nitro- N - nitro - soguanidine (MNNG), gastric mucosal aoptosisindex, and the expression of Bd - 2 and Bax protean were examined in each group respectively. Results:When compared with the PLGC group, Wdkangshu'ning could improve the the expression of Bax and the apoptosisindex (AI), the expression of Bcl - 2 and the ratio of Bcl - 2/Bax was reduced markedly. There were significant differences between the vitacoenzyme group and Weikangshu'ning group. Conclusions: Weikangshu'ning can regulate the expression of Bcl - 2 and Bax protein, influence the ratio of Bcl- 2/Bax, make the apoptosisindex approach control group. So it has obvious curative effects on PLGC and can take a turn for the worse. Therefore. its therapeutic effects are better than that of vitaeoenzyme.
出处
《河南中医》
2007年第9期20-22,共3页
Henan Traditional Chinese Medicine
基金
河南省科技攻关计划项目(编号:072102310010)
河南中医学院苗圃工程课题(编号:2006MP08)
关键词
胃康舒宁
胃癌前病变
BCL-2蛋白
BAX蛋白
大鼠
Weikangshu'ning
preeancer lesions of gastric earcinnoma (PLGC)
Bcl- 2 protein
Bax protein
rats